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Cbl-b is a member of the Cbl family of RING finger E3 ubiquitin ligases and polymorphisms and mutations in 
Cbl-b are associated with several autoimmune/inflammatory diseases in humans. Furthermore, gene targeting 
experiments in mice have provided proof of the in vivo effects of Cbl-b on T cell function and its involvement 
with these diseases. This brief review updates our understanding of Cbl-b in T cell tolerance, proallergic T cell 
development, and cancer immunity in light of the most recent advances, and their impact on autoimmune- 
/inflammatory diseases and cancer immunotherapy. 
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Introduction 
Protein ubiquitination is one of fundamental regulatory 
post-translational modifications regulating intracellular 
signaling and plays potent roles in regulating a variety of 
signals in both innate and adaptive immune cells. The 
selectivity of the ubiquitin-26 S proteasome system for a 
particular substrate protein relies on the interaction 
between an E2 ubiquitin-conjugating enzyme and an E3 
ubiquitin ligase. The unique feature of E3 ubiquitin ligases 
is to recognize substrate proteins and target them for 
ubiquitination [1]. The E3 ubiquitin ligase Cbl-b is a 
member of the highly conserved family of the Cbl (Casitas 
B lineage Lymphoma) proteins. They function as E3 
ubiquitin ligases via their RING finger domain and as 
adaptor proteins via various protein-protein interaction 
domains [2]. Importantly Cbl-b is the only member of the 
Cbl family which has been documented to be crucial for T 
cell tolerance. In this brief review, we summarize the major 
work that we and others have carried out investigating Cbl-
b in T cell tolerance and autoimmunity, proallergic T cell 
development, and cancer immunity.  
Cbl-b in T cell tolerance and Autoimmunity 
The genetic proof of the in vivo biological function of 
Cbl-b comes from gene targeting experiments in mice. Drs. 
Hua Gu and Penninger groups generated Cblb-/- mice 
independently in 2000. Both groups found that Cblb-/- mice 
are highly susceptible to autoimmunity [3, 4], suggests that 
Cbl-b plays a crucial in T cell tolerance induction. 
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Consistent with this notion, we demonstrated that CD28 
costimulation potentiates Cbl-b self- ubiquitination and 
degradation, whereas CTLA-4-B7 interaction induces Cbl-
b expression [5, 6]. As both CD28 and CTLA-4 are critical 
for peripheral T cell tolerance, our findings strongly 
support that Cbl-b is one of the key molecules involved in 
T cell tolerance induction. In support of this, Cbl-b has been 
shown to be required for T cell anergy induction in vitro 
and in vivo [7, 8]. Cbl-b was suggested to target PLC-γ1 and 
PKC-θ for ubiquitination in anergic T cells [7, 8], although it 
is unclear how Cbl-b specifically induces PLC-γ1 and 
PKC-θ ubiquitination in anergic T cells since Cbl-b 
associates with PKC-θ and possibly PLC-γ1 in naïve T 
cells upon TCR/CD28 stimulation [9, 10]. Interestingly, Cbl-
b appears to be important for the conversion of naïve 
CD4+CD25- T cells into CD4+Foxp3+ regulatory T cells 
induced by TGF-β in vitro, and for the peripheral 
generation of CD4+Foxp3+ regulatory T cells [11-13], a 
process that is regulated by the T cell activation threshold 
via an Akt-2-dependent mechanism [13]. In keeping with 
this observation, we found that Cblb-/- T cells display 
heightened Pten inactivation, and hyper-activation of Akt 
[14]. Therefore, Cbl-b regulates T cell tolerance via multiple 
mechanisms (Fig. 1). In support of the importance of Cbl-
b in maintaining T cell tolerance, Cblb-/- mice are highly 
susceptible to experimental autoimmune encephalomyelitis 
(EAE), collagen-induced arthritis (CIA), and autoimmune 
diabetes [4, 8, 15]. These data are further supported by the 
evidence that Cbl-b polymorphisms or mutations have been 
identified in patients with multiple sclerosis and lupus [16, 
17], although the cellular and molecular mechanisms for 
Cbl-b in the development of these diseases remain to be 
determined.  
As mice lacking Cbl-b are highly susceptible to Th17-
mediated autoimmune diseases such as EAE and CIA, it 
was thought that Cbl-b might directly regulate Th17 cell 
differentiation. However, our recent study suggests that 
Cbl-b deficiency does not lead to a biased Th17 cell 
differentiation program [18]. Therefore, the increased Th17 
responses observed during EAE develop- pment may not 
result from T cell-intrinsic loss of Cbl-b, but rather from the 
loss of Cbl-b in innate immune cells. It is envisioned that 
Cbl-b deficiency in innate immune cells, such as dendritic 
cells and macrophages, leads to heightened production of 
pro-inflammatory cytokines which promote Th17 cell 
development. This notion is supported by evidence that 
Cbl-b deficiency results in increased pro-inflammatory 
cytokine production by splenocytes upon LPS stimulation 
[19].  Therefore, it is important to use cell-type-specific 
Cblb knockout strain to dissect the role of Cbl-b in T cells 
vs. non-T cells.  
Cbl-b in proallergic T cell development and allergic 
airway inflammation 
The finding that Cbl-b was not required for Th17 cell 
differentiation was surprising. Using adoptive transfer of 
naive CD4+ T cells from wild type (WT) and Cblb-/- mice 
into Rag1-/- recipients, followed by immunization with 
cardiac myosin peptide in Complete Freund's adjuvant 
(CFA), we found that T cell-intrinsic loss of Cbl-b may not 
account for heightened myocarditis (our unpublished data) 
in a mouse model which has been shown to be mediated by 
Th17 [20, 21].   
To further understanding the role of Cbl-b in Th cell 
differentiation, we performed extensive in vitro Th cell 
differentiation assays. Interestingly, although the in vitro 
generation of Th1 and Th17 cells are comparable between 
WT and Cblb-/-T cells, Th2 and Th9 cell differentiation is 
significantly higher in Cblb-/- mice compared to WT 
controls [18], suggesting that Cbl-b inhibits Th2 and Th9 
cell differentiation. To demonstrate the in vivo biological 
relevance of this observation we utilized a well-established 
mouse model of allergic asthma which has been shown to 
be mediated by both Th2 and Th9 [22]. As expected, mice 
deficient for Cbl-b display severe airway inflammation 
accompanied with heightened Th2 and Th9 cytokines in 
branchoalveolar lavage fluid (BAL), and increased IgE in 
the serum [18]. These data strongly support that Cbl-b 
Figure 1.  Model of Cbl-b in T-cell activation and tolerance. 
Upon TCR stimulation, Pten is inactivated via Nedd4 which targets 
Pten for K63-linked polyubiquitination, and this process is inhibited 
by Cbl-b. Inactivation of Pten leads to the accumulation of PIP3 which 
recruits PDK-1, Vav-1 and Akt to the plasma membrane via its 
interaction with the PH domains within these molecules. Therefore, 
Vav1 links PKC-θ to PDK-1, the former coupling IKKs to the CBM 
complex.  Activated Akt also facilitates the formation of the CBM 
complex possibly by phosphorylating CARMA1. Thus, Cbl-b inhibits 
NF-κB activation via PKC-and Akt. One of the important outcomes 
for Akt activation is that Akt-2 can phosphorylate Foxo1/3a which 
excludes them from the nucleus, thus inhibiting Foxp3 expression 
(not shown). In anergic T cells, Cbl-b targets PLC-γ1 and PKC-θ for 
ubiquitination, thus inhibiting T cell anergy induction. The expression 
of Cbl-b in T cells is controlled by CD28 and CTLA-4. CD28 
costimulation induces Cbl-b ubiquitination and proteasomal 
degradation, while CTLA-4-B7 interaction induces Cbl-b expression. 
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suppresses proallergic Th2 and Th9 development and 
allergic airway inflammation. At the molecular levels Cbl-
b selectively binds to Stat6, a transcription factor which is 
critical for the development of both Th2 and Th9, and 
targets it for polyubiquitination (at K108 and K398) and 
subsequent degradation in the proteasome. Introducing 
Stat6 deficiency into Cblb-/- background completely 
abrogates Th2 responses, and greatly attenuates Th9 
responses [18]. These data suggest that Cbl-b inhibits Th2 
responses in a Stat6-dependent manner, while suppresses 
Th9 via both Stat-6-dependent and -independent 
mechanisms (Fig. 2). In addition, impaired inducible 
regulatory T cell development in the absence of Cbl-b may 
also account for this aberrant Th2 response in a mouse 
model of asthma [13]. In support of a crucial role of Cbl-b in 
allergic asthma, a Cblb D454A mutation has been 
identified as an asthma susceptibility gene variant in 
children [23].  
 Cbl-b in anti-tumor immunotherapy 
The enhanced T cell responses in the absence of Cbl-b 
prompted scientists to determine whether Cbl-b regulates 
anti-tumor immune responses. Deletion of Cbl-b confers 
spontaneous in vivo rejection of tumor cells that express 
human papilloma virus antigens [24]. Introduction of the 
Cbl-b deficiency into tumor-prone ataxia telangiectasia 
mutated–deficient mice markedly reduces the incidence of 
spontaneous thymic lymphomas [25]. Moreover, Cblb-/- 
mice develop significantly fewer ultraviolet B (UVB)-
induced skin malignancies and reject UVB-induced skin 
tumors [24]. Cblb-/- mice also reject transplanted E.G7 and 
EL4 lymphomas [25]. The enhanced anti-tumor activity in 
Figure 2. Model of Cbl-b in proallergic T cell deve- lopment and allergic asthma. Upon stimulation with 
TCR/CD28 and IL-4, Cbl-b binds to Stat6 via its tyrosine residues and TKB domain with SH2 domain and 
phospho-tyrosine of Stat6, respectively. These interactions allow Cbl-b to induce Stat6 polyubiquitination at 
K108 and K398, which leads to the proteasome-mediated degradation. In the absence of Cbl-b, Stat6 
ubuiquitination and degradation is impaired, which results in heightened Th2 and Th9 responses and allergic 
airway inflammation.  Introducing Stat6 deficiency into Cblb-/- mice abrogates hyper-Th2 responses but only 
partially attenuates Th9 responses, suggesting that Cbl-b regulates Th2 cell differentiation via a Stat6-
dependent mechanism but regulates Th9 cell differentiation via both Stat6-dependent and -independent 
mechanisms.  
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the absence of Cbl-b is likely mediated by hyper- activation 
of CD8+ T cells which are resistant to the regulation by 
regulatory T cells or TGF-β [24, 25]. In support of these 
findings, abrogating Cbl-b in effector CD8+ T cells 
improves the efficacy of adoptive therapy of leukemia in 
mice [26].  
Subcutaneous implantation of TC1 tumor cells, as well 
as induction of spontaneous tumors by UV irradiation, 
leads to a significantly delayed outgrowth of tumors in 
Cblb-/- mice when compared to WT mice [24]. Interestingly, 
subcutaneous injection of TC-1 tumor cells into Cblb-/-
Rag2-/- mice, which lack T and B cells, causes a significant 
delay in tumor growth compared to Cblb+/+Rag2-/- 
littermates [27], suggesting that innate cells are involved in 
this process. Further analysis revealed that inactivation or 
deletion of Cbl-b licenses the natural killer (NK) NK cells 
to spontaneously reject metastatic tumors. The heightened 
anti-tumor activity by NK cells lacking Cbl-b is mediated 
by the TAM tyrosine kinase receptors Tyro3, Axl, and Mer. 
Treatment of WT NK cells with a newly-developed small 
molecule TAM kinase inhibitor confers therapeutic 
potential, efficiently enhancing anti-metastatic NK cell 
activity in vivo [27]. Therefore, Cbl-b appears to be a 
therapeutic target for cancer immunotherapy.  
Conclusions 
During the last 14 years, significant progress has been 
made towards our understanding of E3 ubiquitin ligase Cbl-
b in T cell tolerance, autoimmunity, proallergic T cell 
development and allergic asthma, as well as cancer 
immunotherapy. These studies collectively indicate that 
Cbl-b is an excellent drug target for autoimmune disease, 
allergic asthma, and cancers. Future studies will be required 
to identify small molecules that could modify the 
enzymatic function of Cbl-b.  
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